AVE
Director Trades
| Date | Director | Value |
|---|
Company News
Avecho Biotechnology advances CBD insomnia trial with Sandoz licensing deal and funding
Avecho Biotechnology (ASX: AVE) has received a maiden payment of approximately $4.7 million (US$3m) from international generic and biosimilar medicines specialist Sandoz. The payment forms part of a recently signed licensing agreement for the commercial rights to develop Avecho’s proprietary cannabidiol (CBD) product for insomnia treatment in Australia. Avecho has granted Sandoz exclusive commercial rights […]
Avecho Biotechnology signs exclusive licensing deal with Sandoz for CBD insomnia treatment
Avecho Biotechnology (ASX: AVE) has signed an exclusive 10-year development and licensing agreement with Swiss generic pharmaceuticals developer Sandoz Group to investigate the commercialisation of a cannabidiol (CBD) capsule for insomnia in Australia. The companies have identified a market in which nearly 9.5 million Australians experience symptoms of insomnia, with approximately 3.6 million of those […]
Avecho Biotechnology gains traction on commercialising TPM-enhanced oncology drugs
Long-term efforts by Avecho Biotechnology (ASX: AVE) to further the clinical and commercial potential of its TPM (tocopheryl phosphate mixture) enhanced products gained traction during the three months to end June. In May, the US Patent and Trade Marks Office allowed the company a new patent application covering an optimised manufacturing process for TPM. When […]
Avecho Biotechnology passes two-year stability point for CBD soft-gel capsule to treat insomnia
Pharmaceutical company Avecho Biotechnology (ASX: AVE) has passed a crucial two-year stability point milestone for its tocopheryl phosphate mixture (TPM)-enhanced cannabidiol (CBD) soft-gel capsule. Cannabinoids are susceptible to degradation from a number of external sources including oxygen, light, heat and acidity, which can often create challenges with long-term pharmaceutical stability. Specific cannabinoids (such as non-psychoactive […]
Avecho Biotechnology develops first generation TPM edible cannabinoid gummies
Avecho Biotechnology (ASX: AVE) has completed the development of a maiden batch of first generation TPM (tocopheryl phosphate mixture) gummies containing cannabinoids. The company said the chewable, jelly-like product is uniquely positioned to address a range of therapeutic indications including pain, anxiety and sleep issues, as well as neurological and psychiatric disorders. Made from a […]
Avecho Biotechnology allowed new US patent for TPM manufacturing process
The US Patent and Trade Marks Office has allowed Avecho Biotechnology (ASX: AVE) a new patent application directed to an optimised manufacturing process for its drug delivery system tocopheryl phosphate mixture (TPM). TPM is the core technology underpinning Avecho’s product development activities. It has been shown to increase the solubility, stability and absorption of a […]
Avecho Biotechnology signs agreement to advance the use of TPM in leading oncology drugs
Avecho Biotechnology (ASX: AVE) has signed an agreement with Arthur Group LLC for the licensing and development of a series of leading cancer drugs using tocopherol phosphate mixture (or TPM) to replace conventional adverse solvents or surfactants. The strategic partnership includes rights to five of Arthur’s 23 commercial oncology products, representing a combined US total […]
Avecho Biotechnology begins manufacturing CBD capsules for pivotal Phase III insomnia trial
Avecho Biotechnology (ASX: AVE) has announced the start of manufacturing activities to support a pivotal Phase III clinical trial into its oral cannabidoil TPM (tocopheryl phosphate mixture) soft gel capsule for the treatment of insomnia. US-based contract manufacturing organisation Procaps Group will produce the capsules for the trial, which is scheduled to kick off later […]
Avecho Biotechnology poised to begin ‘pivotal’ clinical study of proprietary CBD drug in treating insomnia
Avecho Biotechnology (ASX: AVE) is poised to begin “pivotal” phase III clinical studies evaluating its proprietary cannabidiol (CBD) soft gel capsule in treating insomnia. During the March quarter (Q3 FY2023), Avecho continued development of its products that have been designed with its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery system. The company’s TPM drug delivery […]
Avecho Biotechnology announces $11 million capital raising to fund phase three CBD trial to treat insomnia
Melbourne-based Avecho Biotechnology (ASX: AVE) is seeking to raise $11 million to fund a pivotal clinical trial evaluating the use of its cannabinoid (CBD) soft-gel capsule to treat insomnia. The biotech company has announced an entitlement offer on the basis of one new share for every one existing share held by eligible shareholders at an […]
